George Margaritopoulos

Treatment Response and Safety Profile of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease: A Retrospective Observational Study

Arriana Gkouvi, Maria Boutel, Nikoleta Zioga, Eleni Pagkopoulou et autres

Objective: Interstitial lung disease (ILD) is a significant clinical complication that can occur in various connective tissue diseases (CTDs). Treatment includes immunosuppressants to reduce inflammation, while the antifibrotic nintedanib has been approved for slowing lung function decline in certain CTD-ILD patients. We …

gr (code pays fourni par la source)

Pulmonary vasculitis

George Margaritopoulos, Athol U. Wells

“Regression to the truth”: lessons learned from negative IPF trials

Athina Trachalaki, Anna Lindahl, Simone Petrarulo, George Margaritopoulos

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with limited treatment options. Despite the approval of pirfenidone and nintedanib that slow disease progression, IPF remains a disease with poor survival. Promising therapeutic candidates were tested as potential treatments for IPF and …

gb, fi, it, gr (code pays fourni par la source)

Imaging in the diagnosis and management of fibrosing interstitial lung diseases

Christoph Lederer, Monika Storman, Ádám Domonkos Tárnoki, Dávid László Tárnoki et autres

High-resolution computed tomography (HRCT) plays a pivotal role in the diagnosis and management of interstitial lung diseases (ILDs), particularly given the approval of antifibrotic agents for conditions like idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Diagnosing fibrotic pulmonary disorders through HRCT involves …

de, pl, hu, gr, gb, at (code pays fourni par la source)

Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortality

George Margaritopoulos, Αthanasia Proklou, Athina Trachalaki, Diana Badenes Bonet et autres

Background: Overnight desaturation predicts poor prognosis across interstitial lung diseases (ILDs). The aim of the present study was to investigate whether nocturnal desaturation is associated with pulmonary vasculopathy and mortality. Methods: A retrospective single centre study of 397 new ILD patients was …

gb, gr, es (code pays fourni par la source)

Recent advances in the treatment of systemic sclerosis associated interstitial lung disease

Antoniya Kamenova, Αrgyris Τzouvelekis, George Margaritopoulos

Connective tissue diseases (CTDs) are a heterogenous group of systemic inflammatory disorders. The development of connective tissue disease-associated interstitial lung disease (CTD-ILD) is a key complication associated with significant morbidity and mortality. The aim of this review is to explore the pathogenesis …

gr (code pays fourni par la source)

Systemic Sclerosis and the Lung

Athol U. Wells, George Margaritopoulos, Κατερίνα Αντωνίου, Andrew G. Nicholson

gb (code pays fourni par la source)

Bilateral mediastinal lymphadenopathy with cough and shortness of breath

Antoniya Kamenova, Tara Sathyamoorthy, Gillian Bain, Patrizia Viola et autres

Silicosis and sarcoidosis have very similar radiological appearances and a thorough occupational history may be the only clue to the diagnosis https://bit.ly/3Usxcj7

gb (code pays fourni par la source)

Short‐term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis

Claudio Macaluso, Cristina Boccabella, Maria Kokosi, Nishanth Sivarasan et autres

BACKGROUND AND OBJECTIVE: A proportion of patients with fibrotic hypersensitivity pneumonitis (fHP) follow a progressive disease course despite immunosuppressive treatment. Little is known about predictors of mortality in fHP. We aimed to investigate the impact of short-term lung function changes in fHP …

gb, it, us (code pays fourni par la source)

Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality

Eliza Tsitoura, Athina Trachalaki, Eirini Vasarmidi, Semeli Mastrodemou et autres

Within the Interstitial Lung Diseases (ILD), patients with idiopathic pulmonary fibrosis (IPF) and a subset of those with non-IPF fibrotic ILD have a distinct clinical phenotype of progression despite management. This group of patients has been collectively termed the progressive fibrotic phenotype …

gr, gb (code pays fourni par la source)

Patient symptoms following discharge from hospital after COVID-19 pneumonia

Laurence Pearmain, Cristina Avram, Veronica Yioe, P Webb et autres

Introduction The recovery of patients after COVID-19 has been poorly described Related coronavirus infections (SARSCOV1 and MERS) have protracted recovery time-courses with significant respiratory morbidity,1 suggesting the same may be true for COVID-19 A service evaluation was therefore undertaken to evaluate the …

Serum markers of pulmonary epithelial damage in systemic sclerosis‐associated interstitial lung disease and disease progression

Carmel Stock, Rachel K. Hoyles, Cécile Daccord, Maria Kokosi et autres

BACKGROUND AND OBJECTIVE: The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is highly variable, and accurate prognostic markers are needed. KL-6 is a mucin-like glycoprotein (MUC1) expressed by type II pneumocytes, while CYFRA 21-1 is expressed by alveolar and bronchiolar epithelial …

gb, us, ch, it (code pays fourni par la source)